| Literature DB >> 33118028 |
Angeliki Zarkali1, Peter McColgan2, Mina Ryten3, Regina Reynolds3, Louise-Ann Leyland1, Andrew J Lees4, Geraint Rees5,6, Rimona S Weil1,6,7.
Abstract
Visual hallucinations are common in Parkinson's disease and are associated with poorer prognosis. Imaging studies show white matter loss and functional connectivity changes with Parkinson's visual hallucinations, but the biological factors underlying selective vulnerability of affected parts of the brain network are unknown. Recent models for Parkinson's disease hallucinations suggest they arise due to a shift in the relative effects of different networks. Understanding how structural connectivity affects the interplay between networks will provide important mechanistic insights. To address this, we investigated the structural connectivity changes that accompany visual hallucinations in Parkinson's disease and the organizational and gene expression characteristics of the preferentially affected areas of the network. We performed diffusion-weighted imaging in 100 patients with Parkinson's disease (81 without hallucinations, 19 with visual hallucinations) and 34 healthy age-matched controls. We used network-based statistics to identify changes in structural connectivity in Parkinson's disease patients with hallucinations and performed an analysis of controllability, an emerging technique that allows quantification of the influence a brain region has across the rest of the network. Using these techniques, we identified a subnetwork of reduced connectivity in Parkinson's disease hallucinations. We then used the Allen Institute for Brain Sciences human transcriptome atlas to identify regional gene expression patterns associated with affected areas of the network. Within this network, Parkinson's disease patients with hallucinations showed reduced controllability (less influence over other brain regions), than Parkinson's disease patients without hallucinations and controls. This subnetwork appears to be critical for overall brain integration, as even in controls, nodes with high controllability were more likely to be within the subnetwork. Gene expression analysis of gene modules related to the affected subnetwork revealed that down-weighted genes were most significantly enriched in genes related to mRNA and chromosome metabolic processes (with enrichment in oligodendrocytes) and upweighted genes to protein localization (with enrichment in neuronal cells). Our findings provide insights into how hallucinations are generated, with breakdown of a key structural subnetwork that exerts control across distributed brain regions. Expression of genes related to mRNA metabolism and membrane localization may be implicated, providing potential therapeutic targets.Entities:
Keywords: Parkinson’s disease; controllability; diffusion weighted imaging; regional gene expression; visual hallucinations
Mesh:
Substances:
Year: 2020 PMID: 33118028 PMCID: PMC7719028 DOI: 10.1093/brain/awaa270
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 13.501
Figure 1Overview of the study methodology. (A) Anatomically constrained tractography was used to determine white matter streamlines from diffusion weighted imaging data for each participant. Diffusion data were combined with an anatomical parcellation of 379 brain regions (360 cortical, 19 subcortical) using the Glasser atlas to generate a connectivity matrix for each participant. (B) Structural connectomes were compared between groups. First, global topology metrics (degree strength, path length, clustering coefficient) and controllability were calculated for each participant and compared between Parkinson’s disease (PD) and controls, and PD-VH and PD-non-VH. Second, network-based statistics was performed (contrasts of interest Parkinson’s disease versus controls and PD-VH versus PD-non-VH, age and total intracranial volume included as covariates) resulting to the identification of a VH-subnetwork of reduced connectivity strength. (C) Gene expression data were extracted from the AHBA and mapped into the 180 cortical regions from the left hemisphere according to our anatomical parcellation and an average regional gene expression was calculated for each gene for each cortical region. Gene co-expression network analysis was then performed for the 180 regions resulting to a network of 27 modules. (D) The modules of the resulting gene co-expression network were further examined to identify the modules associated with the VH subnetwork: the summary profile (eigengene) for each module was correlated with presence in the VH subnetwork. Two modules were significantly associated after correction for multiple comparisons, one down-weighted (cyan module) and one up-weighted (greenyellow module). Gene significance (the absolute value) of correlation between the gene and the trait (region’s presence in the VH subnetwork) was then calculated for each gene of the two VH-associated module. Enrichment analyses were then performed using the gene lists for these two modules, ranked by gene significance. F = frontal; L = limbic; O = occipital; P = parietal; S = subcortical; T = temporal.
Demographics and clinical assessments in patients with PD-VH and PD-non-VH patients
| Attribute | Controls | PD-non-VH | PD-VH | Statistic |
|
|---|---|---|---|---|---|
| Demographics | |||||
| Age, years | 66.4 (9.3) | 64.4 (7.8) | 64.6 (8.2) | r2 = 0.003 | 0.459 |
| Male (%) | 16 (47.1) | 47 (58.0) | 6 (31.6) | r2 = 0.022 | 0.086 |
| Years in education | 17.6 (2.3) | 16.9 (2.7) | 17.1 (3.5) | r2 = 0.004 | 0.490 |
| Total intracranial volume, ml |
|
|
|
|
|
| Mood (HADS) | |||||
| Depression score | 1.6 (2.0) | 3.8 (2.9) | 4.8 (3.2) | r2 = 0.120 | <0.001 |
| Anxiety score |
|
|
| r2 = |
|
| Vision | |||||
| LogMAR, best | −0.08 (0.23) | −0.08 (0.16) | −0.06 (0.15) | r2 = 0.013 | 0.854 |
| Pelli Robson, best | 1.79 (0.2) | 1.79 (0.2) | 1.70 (0.2) | r2 = 0.016 | 0.127 |
| D15, total error score | 1.29 (1.2) | 1.28 (1.1) | 1.56 (1.6) | r2 = 0.010 | 0.689 |
| Cognition | |||||
| MMSE | 29.0 (1.0) | 28.9 (1.1) | 28.6 (1.8) | r2 = 0.004 | 0.485 |
| MoCA | 28.8 (1.3) | 28.0 (2.1) | 26.9 (3.1) | r2 = 0.051 | 0.011 |
| Disease specific measures | |||||
| UPDRS | – |
|
|
|
|
| UPDRS part 3 (motor score) | – | 21.8 (11.2) | 29.2 (20.8) | U = 604 | 0.129 |
| UM-PDHQ (hallucination severity score) | – |
|
| – | – |
| LEDD, mg | – | 456.9 (265.0) | 434.9 (210.3) | U = 787 | 0.948 |
| Dopamine agonist use (%) | – | 48 (59.3) | 9 (47.4) | χ2 = 39.59 | 0.999 |
| Amantadine use (%) | – | 8 (9.8) | 1 (5.3) | χ2 = 57.09 | 0.998 |
| Disease duration | – | 4.0 (2.5) | 4.8 (3.4) | U = 669.5 | 0.339 |
| Sniffin’ sticks | – | 7.8 (3.1) | 6.1 (3.4) | U = 940.5 | 0.159 |
| RBDSQ | – |
|
|
|
|
All data shown are mean (SD) except where stated otherwise. Characteristics that significantly differed between the PD-VH and PD-non-VH are highlighted in bold.
Significant difference between PD-VH and PD-non-VH.
Significant difference between PD-non-VH and controls.
Significant difference between PD-VH and controls.
Best binocular score used; LogMAR: lower score implies better performance, Pelli Robson: higher score implies better performance.
HADS = Hospital Anxiety and Depression Scale; LEDD = total levodopa equivalent dose; MMSE = Mini-Mental State Examination; MoCA = Montreal Cognitive Assessment; RBDSQ = REM Sleep Behaviour Disorder Screening Questionnaire; UM-PDHQ = University of Miami Hallucinations Questionnaire (max score = 14); UPDRS = Unified Parkinson’s Disease Rating Scale.
Characteristics of hallucinations experienced by PD-VH patients
| Hallucination characteristics | PD-VH ( |
|---|---|
| Phenotype | |
| Complex hallucinations | 11 (57.9%) |
| Minor hallucinations | 8 (42.1%) |
| Frequency | |
| <1 a week | 11 (57.9%) |
| >1 a week | 8 (42.1%) |
| Duration | |
| <1 s | 8 (42.1%) |
| <10 s | 6 (31.6%) |
| >10 s | 5 (26.3%) |
| Insight | |
| Always preserved | 13 (68.4%) |
| Sometimes preserved | 4 (21.1%) |
| No insight | 2 (10.5%) |
| Number of experienced images mean (SD) | 1 (0.67) |
| Distress | |
| No distress | 14 (73.7%) |
| Mild to moderate distress | 5 (26.3%) |
Participants were asked to reflect on all hallucinatory phenomena experienced within the previous month. Complex hallucinations included well form imagery (people, animals, etc), stationary or animate Minor hallucinations included passage hallucinations as well as non-formed images (shadows etc).
Figure 2The VH subnetwork. Network based statistical analysis revealed a subnetwork of reduced connectivity strength in PD = VH patients, which comprised 92 edges and 82 nodes. The subnetwork was visualized using BrainNetViewer (Xia ).
Figure 3Reduced controllability in patients with Parkinson’s and hallucinations. (A) Controllability ranking across control participants, visualized using PySurfer (https://pysurfer.github.io/). (B) Average controllability in the whole brain network in control participants, PD-non-VH patients PD-VH patients. (C) Average controllability in the VH-subnetwork in control participants, PD-non-VH and PD-VH.
Figure 4Gene expression patterns associated with the VH subnetwork. (A) Significant GO terms for biological processes plotted in semantic space, where similar terms are clustered together. The top five most significant GO terms are labelled for each analysis. Redundant GO terms have been excluded. Markers are scaled based on the log10 q-value for the significance of each GO term. Large blue circles are highly significant, while red circles are less significant (see colour bar). (B) EWCE for the VH-associated modules using the AIBS dataset. Data are presented as standard deviations from the mean. *Statistically significant (FDR corrected) results.